Brief Communication: Comparison of Changes in Metabolic Parameters Following Antiretrovial Therapy with Treatment Regimens Containing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2025 Mar 16

PMID 40089788

Authors

Hamed Mirmoezzi

Hamid Emadi Koochak

Seyed Ali Dehghan Manshadi

Malihe Hasannezhad

SeyedAhmad SeyedAlinaghi

Kiavash Semnani

Ladan Abbasian

Sara Ghaderkhani

Affiliations

Soon will be listed here.

Abstract

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus - 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.

References

Sax P, Erlandson K, Lake J, McComsey G, Orkin C, Esser S . Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019; 71(6):1379-1389. PMC: 7486849. DOI: 10.1093/cid/ciz999. View

Ruderman S, Crane H, Nance R, Whitney B, Harding B, Mayer K . Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era. J Acquir Immune Defic Syndr. 2020; 86(3):339-343. PMC: 7878311. DOI: 10.1097/QAI.0000000000002556. View

Mounzer K, Brunet L, Hsu R, Fusco J, Vannappagari V, Henegar C . Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Res Hum Retroviruses. 2021; 37(11):852-861. DOI: 10.1089/AID.2020.0287. View

Hill A, Hughes S, Gotham D, Pozniak A . Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. J Virus Erad. 2018; 4(2):72-79. PMC: 5892670. View

Di Perri G . Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2022; 29(4):526-529. PMC: 8805468. DOI: 10.53854/liim-2904-4. View

Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard H, Stockle M . Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Ann Intern Med. 2021; 174(6):758-767. DOI: 10.7326/M20-4853. View

Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille M, Donga P . Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States. J Health Econ Outcomes Res. 2022; 9(1):39-49. PMC: 8843358. DOI: 10.36469/jheor.2022.31825. View

Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr P . Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV. Clin Infect Dis. 2024; 79(4):990-998. PMC: 11478808. DOI: 10.1093/cid/ciae189. View

Hill A . Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?. Clin Infect Dis. 2024; 79(4):1006-1009. DOI: 10.1093/cid/ciae190. View

10.

Huhn G, Shamblaw D, Baril J, Hsue P, Mills B, Nguyen-Cleary T . Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infect Dis. 2020; 7(1):ofz472. PMC: 6954396. DOI: 10.1093/ofid/ofz472. View

11.

Moschopoulos C, Protopapas K, Thomas K, Kavatha D, Papadopoulos A, Antoniadou A . Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study. AIDS Res Hum Retroviruses. 2022; 39(2):68-75. DOI: 10.1089/AID.2022.0086. View

12.

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S . Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr. 2017; 76(5):527-531. PMC: 5680113. DOI: 10.1097/QAI.0000000000001525. View

13.

Markakis K, Tsachouridou O, Georgianou E, Pilalas D, Nanoudis S, Metallidis S . Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives. Life (Basel). 2024; 14(11). PMC: 11595778. DOI: 10.3390/life14111367. View

14.

Sapula M, Suchacz M, Zaleski A, Wiercinska-Drapalo A . Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review. Viruses. 2022; 14(1). PMC: 8780416. DOI: 10.3390/v14010122. View

15.

Mallon P, Brunet L, Hsu R, Fusco J, Mounzer K, Prajapati G . Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021; 24(4):e25702. PMC: 8035674. DOI: 10.1002/jia2.25702. View

16.

Erlandson K, Carter C, Melbourne K, Brown T, Cohen C, Das M . Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis. 2021; 73(8):1440-1451. DOI: 10.1093/cid/ciab444. View

17.

Squillace N, Ricci E, Menzaghi B, De Socio G, Passerini S, Martinelli C . The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. Drug Des Devel Ther. 2020; 14:5515-5520. PMC: 7751319. DOI: 10.2147/DDDT.S274307. View

18.

Dupont E, Yombi J . Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review. AIDS Rev. 2023; 25(1):54-64. DOI: 10.24875/AIDSRev.22000026. View